Bill > H1303

This bill aims to address the opioid crisis in Massachusetts by establishing new requirements for opioid and benzodiazepine manufacturers. The key provisions are: 1. The Health Policy Commission can require manufacturers to file a "performance improvement plan" if the Commission believes the manufacturer has increased drug prices to comply with a new assessment on opioid and benzodiazepine sales. The plan must include specific strategies and measurable outcomes to improve performance. 2. The bill creates a new "drug stewardship assessment" where manufacturers must pay the lesser of either their share of total gross receipts for covered drugs multiplied by $75 million, or 40% of their gross receipts. This revenue will be deposited into a Substance Abuse Services Fund to support prevention, intervention, recovery, and treatment programs. 3. Manufacturers must report detailed information about their covered drug sales to the Department of Revenue, which can then share this data with the Health Policy Commission. 4. The bill also makes various other amendments related to the Substance Abuse Services Fund to facilitate the implementation of these new policies.